Nuvectis Pharma, Inc. (NVCT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67080T1088
Nuvectis Pharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -27.57 m USD |
| EBIT | -26.44 m USD |
| Net income | -26.44 m USD |
| Diluted EPS – continuing operations | -1.32 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
More stocks
- Xinlei Compressor Co. Ltd. A (301317.SZ)
- Beijing Asiacom Information Technology Co.Ltd (301085.SZ)
- Hemnet Group AB (publ) (HEM.ST)
- Henan Hengxing Science & Technology Co Ltd (002132.SZ)
- Cancom (COK.DE)
- Winall Hi tech Seed (300087.SZ)
- LivsMed (491000.KQ)
- Yabao Pharmaceutical Group Co Ltd (600351.SS)
- Hellenic Exchanges Athens Stock Exchange SA (EXAE.AT)
- China Resources and Environment Co Ltd (600217.SS)
- Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096.SZ)
- Faraday Copper Corp (FDY.TO)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.